Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy

• Published in: Chinese journal of integrative medicine Vol. 26; no. 5; pp. 339 - 344
• Main Authors: Fan, Teng, Quan, Ri-cheng, Liu, Wei-yi, Xiao, Hai-yan, Tang, Xu-dong, Liu, Chi, Li, Liu, Lv, Yan, Wang, Hong-zhi, Xu, Yong-gang, Guo, Xiao-qing, Hu, Xiao-mei
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2020
• Subjects: Medicine; Medicine & Public Health; Original Article; elderly patient; Chinese medicine; Qinghuang Powder; acute myeloid leukemia; arsenic; Realgar
• ISSN: 1672-0415; 1993-0402
• DOI: 10.1007/s11655-019-3050-6

Objective To analyze the overall survival (OS) of elderly acute myeloid leukemia (AML) patients treated with oral arsenic-containing Qinghuang Powder (青黄散, QHP) or low-intensity chemotherapy (LIC). Methods Forty-two elderly AML patients treated with intravenous or subcutaneous LIC (1 month for each course, at least 3 courses) or oral QHP (3 months for each course, at least 2 courses) were retrospectively analyzed from January 2015 to December 2017. The main endpoints of analysis were OS and 1-, 2-, 3-year OS rates of patients, respectively. And the adverse reactions induding bone marrow suppression, digestive tract discomfort and myocardia injury were observed. Results Out of 42 elderly AML patients, 22 received LIC treatment and 20 received QHP treatment, according to patients’ preference. There was no significant difference on OS between LIC and QHP patients (13.0 months vs. 13.5 months, >0.05). There was no significant difference on OS rates between LIC and QHP groups at 1 year (59.1% vs. 70.0%), 2 years (13.6% vs. 15%), and 3 years (4.6% vs. 5.0%, all >0.05). Furthermore, there was no significant difference of OS on prognosis stratification of performance status > 2 (12 months vs. 12 months), age> 75 year-old (12.0 months vs. 12.5 months), hematopoietic stem cell transplant comorbidity index >2 (12 months vs. 13 months), poor cytogenetics (12 months vs. 8 months), and diagnosis of secondary AML (10 months vs. 14 months) between LIC and QHP patients (>0.05). Conclusion QHP may be an alternative treatment for elderly AML patients refusing LIC therapy.